Clinical Scorecard: What Can Skin Reveal About Dementia?

At a Glance

Key Highlights

• Clinical symptoms can overlap across dementias, and mixed pathologies may contribute to a patient’s presentation.
• Skin biopsy testing can identify whether cutaneous P-SYN is detected.
• In the Syn-D study, cutaneous P-SYN was detected in participants with mild cognitive impairment associated with suspected dementia with Lewy bodies before they met clinical criteria for dementia.
• A six-month DLB study estimated an approximately 52% annualized increase in cutaneous P-SYN from baseline.
• Some Syn-D participants had both cutaneous P-SYN and abnormal p-tau 217 findings.

Guideline-Based Recommendations

Diagnosis

• Use skin-biopsy P-SYN findings as additional information alongside established clinical assessments and biomarkers; the source does not present this test as a standalone diagnosis.
• Consider that P-SYN and p-tau 217 findings may indicate coexisting Lewy body and Alzheimer’s disease-associated pathologies.

Management

• The source describes skin biopsy as potentially complementary to blood biomarkers, cerebrospinal fluid testing, and brain imaging.
• Quantitative skin-biopsy analysis is investigational and is being studied for research use.

Monitoring & Follow-up

• Longitudinal studies reported increasing cutaneous P-SYN levels; further research is needed to clarify the role of quantitative measurements in tracking disease-related changes.
• The source identifies evaluation of treatment effects as a potential future research application, not an established clinical use.

Risks

• Overlapping symptoms and mixed pathologies can make it difficult to distinguish Alzheimer’s disease from dementia with Lewy bodies and other neurodegenerative conditions.
• The source does not provide information about skin-biopsy complications or other procedural risks.

Patient & Prescribing Data

The article discusses people undergoing evaluation for suspected Alzheimer’s disease or other dementias, including study participants with suspected DLB-associated mild cognitive impairment and patients with DLB.

No treatment regimen or prescribing data are provided. The article describes P-SYN skin biopsy as a potential biomarker approach and quantitative analysis as investigational.

Clinical Best Practices

• Interpret biomarker findings in the context of clinical assessment because dementia presentations may overlap and mixed pathologies may occur.
• Treat skin-biopsy P-SYN and Alzheimer’s disease biomarkers such as p-tau 217 as potentially complementary measures, as described in the article.
• Distinguish established detection of P-SYN from investigational quantitative analysis of P-SYN deposition.
• Do not infer treatment response or disease progression from quantitative skin-biopsy results outside the research context described.

Related Resources & Content